Wave Life Sciences Ltd. (WVE) 13F Filing Data & Analysis (Q2 2026)

WVE ranks #2564 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

WVE is a top-conviction position for M28 Capital Management LP — at 56.5% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in WVE belongs to Ra Capital Management, L.p., but the position matters far more to M28 Capital Management LP, who has 56.5% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Algert Global LLC has added to its WVE position for two straight quarters, increasing it by $14.3M to reach $16.4M today.

Fidelity has trimmed its WVE position for two straight quarters, cutting it by $228.7M while still holding $28.6M.

WVE is down 2.3% today, but institutions show net buying of $125.6M this quarter — a divergence between today's price move and the underlying institutional flow.

WVE reported a net loss of $202.5M over the trailing twelve months.

• Not yet profitable — net loss of $202.5M over the trailing twelve months
• Revenue grew 16.5% year over year
• Net income declined year over year, from -$129.9M to -$202.5M
• Operating cash flow was negative, using $187.5M in cash
• Current ratio of 6.47x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.22x equity — within a conventional range